Study Indicates Approved Ebola Antibodies May Be Less Effective Against Bundibugyo Outbreak

A new study published in Nature Communications suggests that existing approved and experimental Ebola monoclonal antibodies may have limited effectiveness against the Bundibugyo virus, which is causing the current 2026 outbreak in the Democratic Republic of Congo and Uganda. Genetic differences in the virus strain are cited as the reason. The outbreak has led to 7,890 confirmed cases and 3,799 deaths, underscoring an urgent need for specific treatments tailored to this particular Ebola species.